Biosergen
Biosergen publishes interim report for first quarter 2023
REG
Summary of the Interim Report for Q1 2023
2023 | 2022 | 2022 | |
TSEK | Jan-Mar | Jan-Mar | Jan-Dec |
Profit/loss | |||
Other income | 5,315 | 1,317 | 5,183 |
Profit/loss before depreciation (EBITDA | -5,029 | -5,018 | -34,129 |
Operating profit/loss before net financials | -5,029 | -5,018 | -34,129 |
Net financials | 2 | 3 | 81 |
Netprofit/loss for the period | -5,027 | -5,015 | -34,048 |
Earnings per share (SEK) | -0.18 | -0.18 | -1.09 |
Highlights during Q1 2023
- March 29, Biosergen provides Phase 2 clinical development strategy update.
- March 13, Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
- January 16, Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial.
Highlights after the period
There have been no highlighe´ts after the period
The Financial report can be found on our website: https://biosergen.net/investors/filings
Datum | 2023-05-31, kl 19:05 |
Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!